FDA warned Chambers' Apothecary that website claims make Blood Pressure Support and CoEnzyme Q10 unapproved new drugs.
What happened
FDA reviewed www.chambersapothecary.com in October 2022 and found order pages for Blood Pressure Support and CoEnzyme Q10 with claims that the products lower blood pressure, lower cholesterol, or improve heart disease. FDA said these claims make the products drugs intended to treat disease, but they are not FDA-approved and lack adequate directions for use.
What FDA found
FDA said the website claims show Blood Pressure Support and CoEnzyme Q10 are intended to cure, mitigate, treat, or prevent disease, which makes them drugs.
section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act [21 U.S.C. 321(g)(1)(B)]FDA said the products are new drugs because they are not generally recognized as safe and effective for the claimed uses and have no FDA approval.
section 201(p) [21 U.S.C. 321(p)]; sections 301(d) and 505(a) [21 U.S.C. 331(d), 355(a)]FDA said the products are misbranded because they do not bear adequate directions for a layperson to use them safely for their intended disease uses.
section 502(f)(1) [21 U.S.C. 352(f)(1)]FDA said introducing these misbranded drugs into interstate commerce violates the Act.
section 301(a) [21 U.S.C. 331(a)]
What FDA wants
FDA asks Chambers' Apothecary to notify it in writing within 15 working days of the specific steps taken to address the violations, with an explanation and supporting documents. If the company cannot complete corrections in that time, FDA asks it to state the reason and the date it will finish.
Who should pay attention
- dietary supplement companies making disease claims
- retailers and online marketplaces selling supplements
- brands selling blood pressure or CoQ10 products
This is a summary. Read the original letter on fda.gov.